Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a proprietary therapy called LUCID-MS, designed to address the unmet need for multiple sclerosis (MS) treatments that directly protect or restore myelin integrity. Multiple sclerosis affects more than 2.8 million people worldwide, including approximately 1 million in the USA, and current therapies often focus on reducing inflammation but may not adequately address neurodegeneration and myelin damage. LUCID-MS targets demyelination and provides neuroprotection to help preserve mobility and bodily function. The company recently completed Phase 1 clinical studies in healthy volunteers, reporting a favorable safety profile and good tolerability. In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, marking a significant milestone.

Multiple sclerosis is a chronic autoimmune and neurodegenerative disease where the immune system attacks the myelin sheath around nerve fibers, disrupting communication between nerves. This leads to symptoms that can progressively impair mobility and quality of life. LUCID-MS aims to halt or reverse this damage, offering hope for patients who continue to experience disability despite existing treatments. The therapy is patented and represents a novel approach to MS care, potentially shifting the focus from symptom management to neuroprotection and repair.

This news is disseminated on behalf of Quantum BioPharma Ltd. and includes paid advertising. For more details, readers can visit the company's newsroom at https://ibn.fm/QNTM or read the full article on BioMedWire. BioMedWire is a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, and is part of the Dynamic Brand Portfolio @ IBN. The company provides press release distribution, editorial syndication to over 5,000 outlets, and social media distribution to millions of followers.